Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Mammoth preparing to seek EUA for CRISPR COVID-19 test

By Tom Salemi | April 16, 2020

Mammoth BiosciencesCRISPR-startup Mammoth Biosciences will file for an emergency use application from the FDA after publishing a study in Nature Biotechnology that suggests its platform can detect SARS-CoV-2 from a respiratory swab RNA extracts in less than 45 minutes.

The company says the paper contains the first peer-reviewed data using CRISPR diagnostics for COVID-19.

In a release, Mammoth says its CRISPR tech offers faster, lower-cost alternatives to traditional quantitative polymerase chain reaction (qRT-PCR) tests. Those tests requires access to a specialized laboratory, typically requiring a 24-hour-plus turnaround, according to the company.

“We need faster, more accessible and scalable diagnostics,” said Janice Chen, chief technology officer of Mammoth, in a release. “The point-of-care testing space is ripe for disruption and CRISPR diagnostics have the potential to bring reliable testing to the most vulnerable environments.”

Chen said CRISPR can be programmed to detect any DNA or RNA sequence. The company reconfigured its DETECTR platform to detect the virus. The company collaborated Charles Chiu, MD, researchers from the Department of Laboratory Medicine at the University of California, San Francisco (UCSF), Dr. James Broughton, the research lead of the study.

The researchers validated the method using contrived reference samples and clinical samples from US patients, including 36 patients with COVID-19 infection and 42 patients with other viral respiratory infections.


Filed Under: Drug Discovery, Genomics/Proteomics, Infectious Disease

 

Comments

  1. Phumlani Mkhize says

    April 20, 2020 at 2:21 am

    I think it is great. What are you guys waiting for? Go for the RNA Genome of the Virus. Use restriction endonuclease from the bacteria. Grow a bacteria in dish and introduce the Coronavirus in the Petri Dishes with bacteria. Or just introduce foreign ssRNA into a Petri Dishe with bacteria and see the bacteria can cut the ssRNA Genome of the Coronavirus. If the bacteria cuts the RNA GENOME of the Coronavirus the next step is to extract the enzyme from the bacteria and test the enzyme in the infected Human alveoli cell culture and see if you can repeat the same process of cutting the ssRNA Genome of the Coronavirus. If it does then we can start celebrating because you have find a way to kill the Virus. The challenging part is to find a bacteria that has the correct restriction endonuclease enzyme to cut.

    Thanks

    Phumlani Mkhize

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE